DDCI-01 / Chongqing Medical University, Chengdu Dikang Pharmaceutical - LARVOL DELTA

DDCI-01 in Pulmonary Arterial Hypertension: A Multicenter Phase II Randomized Active-Controlled Trial (AHA 2025) - "Also, DDCI-01 10 mg significantly improved right ventricular ejection fraction (8.5%), with a greater increase versus tadalafil (LSMD, 6.0%; 95% CI, 0.4 to 11.6; P = 0.038). No treatment-emergent severe adverse events occurred in DDCI-01 2.5 mg group and 10 mg group, whereas 3 (16.7%) in both DDCI-01 20 mg group and tadalafil group.ConclusionDDCI-01 10 mg tented to improve hemodynamics and cardiac function in PAH and was well tolerated, supporting further development in phase 3 trials."

Clinical • P2 data • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

A Multicenter, Randomized, Double-blind, Positive-controlled Clinical Study to Evaluate the Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of DDCI-01 in Patients with Pulmonary Arterial Hypertension (ChiCTR) - P2 | N=72 | Completed | Sponsor: Guangdong Provincial People's Hospital; Chongqing Dikang Erle Pharmaceutical Co., Ltd

New P2 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Evaluation of Safety and Pharmacokinetics of DDCI-01, a Phosphodiesterase Type 5 Inhibitor, in Healthy Participants. (PubMed, Clin Pharmacokinet) - "DDCI-01 demonstrated favorable safety and pharmacokinetic profiles within the dose range. The findings of this first-in-human study support further research for the indications of DDCI-01, such as pulmonary arterial hypertension and erectile dysfunction."

Clinical • Journal • PK/PD data • Cardiovascular • Erectile Dysfunction • Hypertension • Musculoskeletal Pain • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases